Alzamend Neuro, Inc DEFA14A, filed Jun 11, 2024
Alzamend Neuro, Inc. (ALZN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. 1)
| Filed by the Registrant | x | |
| Filed by a Party other than the Registrant | ¨ | |
| Check the appropriate box: | ||
| ¨ | Preliminary Proxy Statement | |
| ¨ | Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) | |
| ¨ | Definitive Proxy Statement | |
| x | Definitive Additional Materials | |
| ¨ | Soliciting Material Pursuant to § 240.14a-12 | |
ALZAMEND NEURO, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| Payment of Filing Fee (Check the appropriate box): | |
| x | No fee required |
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: | |
| (2) | Aggregate number of securities to which transaction applies: | |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |
| (4) | Proposed maximum aggregate value of transaction: | |
| (5) | Total fee paid: |
| ¨ | Fee paid previously with preliminary materials: |
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| (1) | Amount Previously Paid: | |
| (2) | Form, Schedule or Registration Statement No.: | |
| (3) | Filing Party: | |
| (4) | Date Filed: |
ALZAMEND NEURO, INC.
3480 Peachtree Road NE, Second Floor, Suite 103
Atlanta, GA 30326
SUPPLEMENT TO PROXY STATEMENT
FOR
2024 SPECIAL MEETING OF STOCKHOLDERS
The following information supplements and amends the Definitive Proxy Statement (the “Proxy Statement”) of Alzamend Neuro, Inc. (the “Company”) that the Company filed with the Securities and Exchange Commission (the “SEC”) on May 31, 2024 in connection with the solicitation of proxies by the Company’s Board of Directors (the “Board”) for the Company’s Special Meeting of Stockholders (the “Meeting”) to be held in a virtual meeting format only on Monday, July 8, 2024, at 12:00 PM Eastern Time. This corrects and supplements statements concerning the number of shares of Capital Stock that are entitled to vote and the number required to constitute a quorum under the heading “Who is Entitled to Vote; Vote Required; Quorum” on page 2 of the Proxy Statement. This supplement to the Proxy Statement (this “Supplement”) is furnished in connection with the solicitation of proxies by the Board for use at the Meeting. Capitalized terms used in this Supplement and not otherwise defined have the meaning given to such terms in the Proxy Statement.
In calculating the number of votes entitled to be cast at the Meeting, the Company inadvertently calculated 1,719,537 as the number of votes entitled to be cast by the holders of Shares A Preferred Stock, instead of 1,375,310 votes. The former number reflected the number of shares of Common Stock that the outstanding Series A Preferred Stock were convertible into, without regard to the NYSE American rules and regulations, as of the Record Date. The latter number reflects the maximum number of votes that the Series A Preferred Stock is entitled to be cast until such time as Proposal No. 1 has been approved by the Company’s stockholders. The 1,375,310 figured, and the NYSE American limitation, were already disclosed in the second and third paragraphs under the heading. As a result, under the heading “Who is Entitled to Vote; Vote Required; Quorum” on page 2, the third and fourth paragraphs under this heading are hereby amended and restated in their entirety to read as follows:
A majority of the total votes entitled to be cast will constitute a quorum at the Meeting; of the 11,157,921 outstanding shares of Capital Stock, or 5,578,961 such shares, will constitute a quorum at the Meeting, provided that no more than 1,375,310 shares of Series A Preferred Stock and Common Stock held by the Investor that may be voted will be counted as part of the Capital Stock, as only a portion of the Common Stock and Series A Preferred Stock held by the Investor will be eligible to vote on the matters to be presented to the stockholders.
Accordingly, for purposes of the votes eligible to be cast at the Meeting, the term “Eligible Capital Stock” as used herein shall mean 9,782,611 such shares for purposes of Proposal No. 1 and 11,157,921 such shares for purposes of Proposal No. 2.
Except as set forth in this Supplement, all information set forth in the Proxy Statement remains unchanged. Please note that this Supplement does not change the proposals to be acted upon at the Meeting, which are described in the Proxy Statement.
Date: June 11, 2024